Search

Displaying results 9241 - 9250 of 10000 in total
  1. Drug

    VB-201

    go.drugbank.com/drugs/DB15259
    Investigational

    VB-201 is under investigation in clinical trial NCT01001468 (Study to Assess VB-201 in Patients With Psoriasis).

  2. Drug

    Batabulin

    go.drugbank.com/drugs/DB16103
    Investigational

    Batabulin is under investigation in clinical trial NCT00057382 (T138067 Versus Doxorubicin in Chemotherapy-naive, Unresectable, Hepatocellular Carcinoma Patients).

  3. Drug

    GSK232802

    go.drugbank.com/drugs/DB16110
    Investigational

    GSK232802 is under investigation in clinical trial NCT00604825 (Treatment of Hot Flashes/flushes in Postmenopausal Women (WARM Study)).

  4. Drug

    Efungumab

    go.drugbank.com/drugs/DB16151
    Investigational

    Efungumab is under investigation in clinical trial NCT00217815 (Preliminary Study of Mycograb and Docetaxel in Advanced Breast Cancer).

  5. Drug

    β-Methylfentanyl

    go.drugbank.com/drugs/DB09171
    ExperimentalIllicit

    β-Methylfentanyl is an analgesic of the _opioid_ class. It is an analog of the potent opioid, fentanyl.

  6. Drug

    Denifanstat

    go.drugbank.com/drugs/DB17576
    Investigational

    Denifanstat is an orally bioavailable fatty acid synthase (FASN) inhibitor. Due to its antineoplastic activities, it is being investigated for various cancers.

  7. Drug

    8-azaguanine

    go.drugbank.com/drugs/DB01667
    Experimental

    8-azaguanine is one of the early purine analogs showing antineoplastic activity. It functions as an antimetabolite and is easily incorporated into ribonucleic acids.

  8. Drug

    Clopamide

    go.drugbank.com/drugs/DB13792
    Investigational

    Clopamide is an oral diuretic agent with antihypertensive activity. Like thiazide diuretics, it has an aromatic sulfonamide base but with no double-ring structure.

  9. Drug

    NDX-3315

    go.drugbank.com/drugs/DB18671
    Investigational

    NDX-3315 is an investigational radiopharmaceutical agent for the diagnosis, treatment monitoring, and management of eosinophilic esophagitis. It is a technetium-99m radiolabeled [heparin].

  10. Drug

    VAD-044

    go.drugbank.com/drugs/DB17697
    Investigational

    VAD-044 is an allosteric AKT inhibitor developed by Vaderis Therapeutics AG. It is being investigated for the treatment of Hereditary Hemorrhagic Telangiectasia.[L46098]